Aricept (donepezil hydrochloride) + placebo
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Mild Cognitive Impairment
Conditions
Mild Cognitive Impairment
Trial Timeline
Feb 1, 2006 → Sep 1, 2007
NCT ID
NCT00934375About Aricept (donepezil hydrochloride) + placebo
Aricept (donepezil hydrochloride) + placebo is a approved stage product being developed by Eisai for Mild Cognitive Impairment. The current trial status is completed. This product is registered under clinical trial identifier NCT00934375. Target conditions include Mild Cognitive Impairment.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00754013 | Phase 3 | Terminated |
| NCT00934375 | Approved | Completed |
Competing Products
20 competing products in Mild Cognitive Impairment